Abstract 1250P
Background
We conducted a retrospective analysis to evaluate the volume of the lungs and determine the presence of infiltration and consolidation. To accurately interpret anisotropies and voxel spacings and to maintain resilience even when dealing with unbalanced class distributions, we used nnU-Net with quantitative and qualitative assessments to detect Lung infiltration. Utilizing TCGA-LUAD data (Lung Adenocarcinoma) and TCGA-LUSC (Lung Squamous cell carcinoma) this retrospective study on segmentation for volumetric and consolidation assessments are conducted. Chest OMX is a diagnostic tool that can assess lung volume, which in turn enables various applications such as monitoring recurrence from the changes in Lung volume; identifying infiltration and response to the treatment from Lung Volume and lobes, and detecting abnormalities in the lung from Consolidation. By providing quantitative score values, it assists in tracking changes over time and facilitating decision-making in clinical diagnosis.
Methods
We used nnU-Net, a popular deep-learning framework designed for medical image segmentation tasks. By analyzing the volume, infiltration, and consolidation characteristics of a lung carcinoma on CT scans, we can assess the tumor's behavior and response to treatment. From regional lung segmentation invasion, the burden is calculated. Additionally, measurements of discovered lung lesions and dedication to the relevant lung lobe are performed, along with fully automated lung lobe segmentation. Lobe 3D uses a deep learning system to measure the volume of the five lobes of the lung. HAA is also analyzed towards the end. Patient cases are selected irrespective of their ages from the TCGA cohort group. The primary outcome was the assessment of lung volume and the extent of the infiltration.
Results
Table: 1250P
Chest OMX: Generated diagnosis report for the case TCGA-LUSC
Left lung (LL) cm3 | 1429.50 |
Right lung (RL) cm3 | 1516.38 |
Left upper lobe (LUL) cm3 | 807.24 |
Left lower lobe (LLL) cm3 | 603.17 |
Right upper lobe (RUL) cm3 | 618.34 |
Right middle lobe (RML) cm3 | 276.84 |
Right lower lobe (RLL) cm3 | 611.89 |
Left upper lobe (HAA) cm3 | 170.16 |
Left lower lobe (HAA) cm3 | 378.00 |
Right upper lobe (HAA) cm3 | 128.18 |
Right middle lobe (HAA) cm3 | 59.05 |
Right lower lobe (HAA) cm3 | 394.12 |
Volume (LUL, LLL, RUL, RML, RLL) cm3 | (807.24, 603.17, 618.34, 276.84, 611.89) |
Involvement (LUL, LLL, RUL, RML, RLL) cm3 | (378.00, 128.18, 59.05, 394.12) |
Infiltration percentage (LUL, LLL, RUL, RML, RLL) % | (21.08, 62.67, 20.73, 21.33, 64.41) |
Conclusions
The diagnostic tool, Chest OMX can analyze the lung tissue from CT scans to determine the volume, consolidation and extent of infiltration by cancerous cells.
Clinical trial identification
Editorial acknowledgement
The dataset acknowledgment for,
1.Albertina, B., Watson, M., Holback, C., Jarosz, R., Kirk, S., Lee, Y., Rieger-Christ, K., & Lemmerman, J. (2016). The Cancer Genome Atlas Lung Adenocarcinoma Collection (TCGA-LUAD) (Version 4) [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/K9/TCIA.2016.JGNIHEP5.[Data Citation]
2. Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S., Maffitt, D., Pringle, M., Tarbox, L., & Prior, F. (2013). The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository. In Journal of Digital Imaging (Vol. 26, Issue 6, pp. 1045–1057). Springer Science and Business Media LLC. \https://doi.org/10.1007/s10278-013-9622-7.[TCIA Citation]
3.Kirk, S., Lee, Y., Kumar, P., Filippini, J., Albertina, B., Watson, M., Rieger-Christ, K., & Lemmerman, J. (2016). The Cancer Genome Atlas Lung Squamous Cell Carcinoma Collection (TCGA-LUSC) (Version 4) [Data set]. The Cancer Imaging Archive. \https://doi.org/10.7937/K9/TCIA.2016.TYGKKFMQ.[Data Citation]
Legal entity responsible for the study
PMX.Inc., USA and PMX, South Korea.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14